Sociedad Americana de Hirudoterapia

Antiphospholipid syndrome, antiphospholipid antibodies, and stroke.

Review published in International journal of stroke : official journal of the International Stroke Society (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosDesarrollo de fármacosMittal et al. · International journal of stroke : official journal of the International Stroke Society, 2023

Abstract

Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disease with heterogeneous clinicopathological manifestations and is a well-established cause of acute ischemic stroke (AIS) and transient ischemic attack (TIA), particularly in younger patients. There is growing recognition of a wider spectrum of APS-associated cerebrovascular lesions, including white matter hyperintensities, cortical atrophy, and infarcts, which may have clinically important neurocognitive sequalae. Diagnosis of APS-associated AIS/TIA requires expert review of clinical and laboratory information. Management poses challenges, given the potential for substantial morbidity and recurrent thrombosis, additional risk conferred by conventional cardiovascular risk factors, and limited evidence base regarding optimal antithrombotic therapy for secondary prevention. In this review, we summarize key features of APS-associated cerebrovascular disorders, with focus on clinical and laboratory aspects of diagnostic evaluation. The current status of prognostic markers is considered. We review the evidence base for antithrombotic treatment in APS-associated stroke and discuss uncertainties, including the optimal intensity of anticoagulation and efficacy of direct oral anticoagulants. Clinical practice recommendations are provided, covering antithrombotic treatment, supportive management, and options for anticoagulant-refractory cases, and we highlight the benefits of adopting a considered, multidisciplinary team approach.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansAntiphospholipid SyndromeStrokeIschemic StrokeFibrinolytic AgentsIschemic Attack, TransientAntibodies, AntiphospholipidAnticoagulants

Resumen

Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disease with heterogeneous clinicopathological manifestations and is a well-established cause of acute ischemic stroke (AIS) and transient ischemic attack (TIA), particularly in younger patients. There is growing recognition of a wider...

Por qué esto importa para la hirudoterapia

This review summarizes the clinical and laboratory aspects of antiphospholipid syndrome (APS) associated with stroke and transient ischemic attacks, focusing on diagnostic evaluation and antithrombotic treatment strategies. It discusses the challenges of optimal anticoagulation intensity and the limited evidence base regarding the efficacy of direct oral anticoagulants for secondary prevention in this prothrombotic autoimmune disease. The abstract provides clinical practice recommendations strictly for conventional pharmacological treatments, including options for anticoagulant-refractory cases. It does not mention leeches, hirudotherapy, or the leech secretome, making its connection to the American Society of Hirudotherapy strictly indirect and limited to general thrombosis management.

Citación

Antiphospholipid syndrome, antiphospholipid antibodies, and stroke.

Mittal et al. · International journal of stroke : official journal of the International Stroke Society, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.